Premium
Measurable residual disease testing for personalized treatment of acute myeloid leukemia
Author(s) -
Ehinger Mats,
Pettersson Louise
Publication year - 2019
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12926
Subject(s) - hematologist , acute promyelocytic leukemia , medicine , myeloid leukemia , minimal residual disease , npm1 , leukemia , oncology , disease , myeloid , immunology , intensive care medicine , biology , genetics , retinoic acid , karyotype , chromosome , gene
This review summarizes – with the practicing hematologist in mind – the methods used to determine measurable residual disease ( MRD ) in everyday practice with some future perspectives, and the current knowledge about the prognostic impact of MRD on outcome in acute myeloid leukemia ( AML ), excluding acute promyelocytic leukemia. Possible implications for choice of MRD method, timing of MRD monitoring, and guidance of therapy are discussed in general and in some detail for certain types of leukemia with specific molecular markers to monitor, including core binding factor ( CBF )‐leukemias and NPM 1 ‐mutated leukemias.